Business context and reporting period
Stepan Company filed its Form 10-K for the fiscal year ended December 31, 2023. The filing reports full-year results; it does not provide clear standalone fourth-quarter financial results. Stepan manufactures specialty and intermediate chemicals for other manufacturers. Its reportable segments are Surfactants, Polymers and Specialty Products, representing 69%, 28% and 3% of 2023 net sales, respectively.
Financial performance and position
Unless otherwise indicated, amounts are in millions of dollars. Fiscal 2023 compared with fiscal 2022:
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales | $2,325.8 | $2,773.3 | -16% |
| Gross profit / margin | $277.6 / 11.9% | $427.1 / 15.4% | -$149.5 |
| Operating income / margin | $58.6 / 2.5% | $207.3 / 7.5% | -72% |
| Net income attributable to Stepan | $40.2 | $147.2 | -73% |
| Diluted EPS | $1.75 | $6.38 | Down $4.63 |
| Adjusted net income (non-GAAP) | $50.7 | $153.5 | -67% |
| Cash from operations | $174.9 | $160.8 | +$14.1 |
| Capital expenditures | $260.3 | $301.6 | -$41.3 |
| Cash and cash equivalents at year-end | $129.8 | $173.8 | -$43.9 |
| Total debt at year-end | $654.1 | $587.1 | +$67.0 |
| Net debt | $524.3 | $413.3 | +$110.9 |
Cash from operations less capital expenditures was approximately negative $85.5 million in 2023, versus negative $140.8 million in 2022. Working capital was a $13.4 million cash source, mainly reflecting inventory reductions. Current assets were $851.9 million and current liabilities $607.9 million at year-end. Cash included $108.3 million held by non-U.S. subsidiaries. The revolving credit agreement and term loan had $283.0 million outstanding, with $151.1 million available after letters of credit. Scheduled debt obligations due within one year were $252.9 million. Net debt to net debt plus equity increased to 30.1% from 26.2%.
Segment sales and operating income fell across all three businesses. Surfactants sales were $1,602.8 million and operating income $72.4 million (down 15% and 56%); Polymers sales were $642.5 million and operating income $60.8 million (down 19% and 27%); Specialty Products sales were $80.5 million and operating income $11.5 million (down 21% and 62%).
Material changes versus the prior period
- Consolidated sales volume fell 11%, reducing sales by $292.2 million; lower average selling prices reduced sales by a further $182.4 million. Currency translation added $27.1 million.
- Lower demand and significant customer and channel inventory destocking weighed on Surfactants and Polymers. Polymer demand was also affected by reduced construction activity and customer share loss in Europe. Specialty Products was affected by lower MCT product volume and margins.
- Operating income declined $148.7 million. Segment operating income decreased $130.9 million in total; corporate expenses also rose, including higher deferred compensation and restructuring/impairment charges.
- Net interest expense rose to $12.1 million from $9.8 million, reflecting higher debt balances and rates. The effective tax rate fell to 16.9% from 22.0%.
- Inventory fell to $265.6 million from $402.5 million. Environmental and legal accruals declined to $20.6 million from $32.6 million, while 2023 cash expenditures for environmental remediation and certain legal matters increased to $13.2 million from $2.3 million.
Outlook, risks and unusual items
Management expects 2024 sales volumes and margins to improve, citing a continued recovery in rigid polyols, contracted Surfactant volume growth, an expected agricultural business recovery in the second half, and lower raw material costs than in 2023. Management targets $50 million of pre-tax savings in 2024 from cost-reduction actions. It expects adjusted EBITDA growth and positive free cash flow in 2024. Capital expenditures are forecast at $120 million to $140 million, including completion of the Pasadena, Texas alkoxylation plant, which is expected to start up in the third quarter of 2024. These are management expectations, not guarantees.
- 2023 included $12.0 million of business restructuring and asset impairment charges, including a voluntary early retirement reserve, workforce productivity actions and asset/project write-offs; goodwill and other intangible impairment charges were $2.0 million. Goodwill impairments included Colombia and the Specialty Products/Lipid Nutrition business. The company also reported a $1.0 million environmental remediation expense adjustment in its non-GAAP reconciliation.
- Environmental and legal losses were estimated at $20.6 million to $49.4 million; the company accrued the low end because no amount in the range was considered a better estimate. Maywood remediation costs may change as work is finalized and groundwater decisions emerge. A possible natural-resource-damages claim related to Wilmington is considered probable, but the outcome and allocation are unclear.
- Key risks include chemical manufacturing accidents or disruptions, volatile raw material and energy costs, transportation disruptions, weak end-market demand, competition, regulatory and environmental liabilities, product reformulation (including 1,4-dioxane rules), foreign exchange, cybersecurity, debt and covenant constraints, and delays or cost overruns on capital projects. The company reported no cybersecurity incident since the beginning of 2023 that materially affected or was reasonably likely to materially affect it.
- The company said it was in compliance with material debt covenants at year-end. Its amended debt agreements include leverage, interest coverage and net worth requirements and limits on debt, dividends and share repurchases. The Pasadena facility’s completion and commissioning costs remain execution considerations.
The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting. Critical audit matters included the Maywood environmental contingency and Mexico reporting-unit goodwill valuation; Mexico goodwill was $6.7 million and no impairment was recorded there.
Most important facts for investors to verify
- Whether volume, margins and cash generation recover as management expects in 2024, and whether the $50 million savings target is achieved.
- Pasadena plant startup timing, final project cost, ramp-up performance and related commissioning expenses.
- Debt maturities and refinancing needs, available revolver capacity, covenant headroom and the impact of variable interest rates.
- Environmental reserve adequacy and potential additional exposure at Maywood, Wilmington, D’Imperio and other sites.
- Whether customer destocking, competitive pricing, construction weakness and 1,4-dioxane regulation continue to pressure demand or margins.
- Underlying performance relative to non-GAAP adjusted results, including the effects of restructuring, impairment, deferred compensation and environmental items.